Evidence map›Paper›PMID 42058646›Full record

ArticleHemaSphere2026

A single

Quentin Kimmerlin, Morgane Hilpert, Nils Hansen, Alexandre Guy, Marc Usart, Jan Stetka, Patryk Sobieralski, Tiago Almeida Fonseca, Hui Hao-Shen, Radek C Skoda

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Quentin KimmerlinBaylor College of Medicine Dan L Duncan Comprehensive Cancer Center Houston Texas USA.ORCID https://orcid.org/0000-0002-1999-782X
Morgane HilpertDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.ORCID https://orcid.org/0009-0004-6374-2201
Nils HansenDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.ORCID https://orcid.org/0009-0007-4556-5557
Alexandre GuyDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.ORCID https://orcid.org/0000-0002-8727-4615
Marc UsartBaylor College of Medicine Dan L Duncan Comprehensive Cancer Center Houston Texas USA.ORCID https://orcid.org/0009-0002-4575-8029
Jan StetkaDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.ORCID https://orcid.org/0000-0003-4301-2856
Patryk SobieralskiBaylor College of Medicine Dan L Duncan Comprehensive Cancer Center Houston Texas USA.ORCID https://orcid.org/0000-0001-9112-5017
Tiago Almeida FonsecaDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.
Hui Hao-ShenDepartment of Biomedicine, Experimental Hematology University Hospital Basel and University of Basel Basel Switzerland.
Radek C SkodaBaylor College of Medicine Dan L Duncan Comprehensive Cancer Center Houston Texas USA.ORCID https://orcid.org/0000-0002-3626-9496

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPNs) are clonal disorders of hematopoietic stem cells (HSCs) that are most frequently caused by acquired somatic mutations in

Identifiers

PMID42058646
PMCPMC13123196

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.